Cancer News and Research

Latest Cancer News and Research

Research sheds new light on venous thromboembolism following liver resections

Patients undergoing liver surgery have long been considered to be at low risk of venous thromboembolism. However, pulmonary embolism has recently emerged as an increasingly frequent and potentially fatal complication following liver resections.

1 Feb 2011

$FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma$

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation for carfilzomib, a next generation proteasome inhibitor for the potential treatment of patients with relapsed and refractory multiple myeloma.

1 Feb 2011

Eurogentec, ImaginAb announce collaboration to produce engineered antibody fragments

ImaginAb, and Eurogentec S.A. announce a development collaboration to establish a novel system for producing engineered antibody fragments. The two companies will produce ImaginAb's optimized antibody fragments with Eurogentec's high-performance Pichia pastoris expression system.

1 Feb 2011

New research finding shows strong relationship between gut bacteria and fatty liver

The more we learn about biology, the closer we get to being able to treat disease - and the more complicated our understanding of disease itself becomes. A new research finding showing a strong relationship between complex microbial ecologies in human intestines and the common but serious medical condition known as fatty liver illustrates this paradox.

1 Feb 2011

FDA approves Boston Scientific's Renegade HI-FLO Fathom Pre-Loaded System

Boston Scientific Corporation today announced that the U.S. Food and Drug Administration has approved its Renegade HI-FLO Fathom Pre-Loaded System for selective access and delivery of diagnostic, embolic and therapeutic materials into the peripheral vasculature.

1 Feb 2011

MRI T2 can determine iron overload in beta-thalassemic patients

Iron overload is a common and serious problem in thalassemic major patients. As iron accumulation is toxic in the body's tissues, accurate estimation of iron stores is of great importance in these patients to prevent iron overload by an appropriate iron chelating therapy.

1 Feb 2011

Researchers study peripheral blood Tregs as disease marker of gastric cancer

T-regulatory lymphocytes are a subset of T lymphocytes that are involved in the mechanism of immunotolerance to self- and allo-antigens. Activity of these cells is one of the mechanisms of immune evasion of tumors, which inhibits the antitumor activity of effector cells.

1 Feb 2011

FDA approves ultrasmall silica inorganic nanoparticle INDA for targeted molecular imaging of cancer

Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application from the US Food and Drug Administration for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.

31 Jan 2011

Researchers to develop computer-assisted diagnosis tools for pathologists

Researchers are leveraging Ohio Supercomputer Center resources to develop computer-assisted diagnosis tools that will provide pathologists grading Follicular Lymphoma samples with quicker, more consistently accurate diagnoses.

31 Jan 2011

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

National Jewish Health scientists identify signaling pathway for ALI

Researchers at National Jewish Health have discovered a signaling pathway that is crucial to the devastating effects of acute lung injury. The data, obtained from cells, animals and ALI patients, suggest several potential therapeutic targets. Experimental blockade of one of the targets significantly reduced flooding of the lungs that is the hallmark of ALI.

31 Jan 2011

Empire State Building, NYRR partner with MMRF for new myeloma drugs

For the first time in the 34-year history of the Empire State Building Run-Up, the New York Road Runners has partnered with a nonprofit as the event's Presenting Sponsor.

31 Jan 2011

Lowe's receives CEO Cancer Gold Standard accreditation

Lowe's has received CEO Cancer Gold Standard accreditation, recognizing the company's commitment to reducing the cancer risk of its employees and their families by encouraging healthy lifestyles and promoting early detection through screenings, and by providing quality care, including access to cancer clinical trials, when a cancer diagnosis becomes a reality.

31 Jan 2011

New study: FUS protein appears to inhibit growth of prostate cancer cells in lab

Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.

31 Jan 2011

Alexion announces acquisition of Taligen Therapeutics

Alexion Pharmaceuticals, announced that it has acquired Taligen Therapeutics, a privately held development-stage biotechnology company based in Cambridge, Mass.

31 Jan 2011

Scientists to commence new DNA vaccine trial for use in patients with leukemia

A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.

31 Jan 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

New nicotine addiction mechanism revealed

A new discovery has shown why some people cannot give up tobacco and may lead to new anti-smoking treatments. The researchers have found a brain pathway which when defective leads to an uncontrollable desire to smoke. This is a “sub-unit” of a receptor protein sensitive to nicotine.

31 Jan 2011

Extreme morning sickness drug comes at a price

Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.

31 Jan 2011

$61 million anti-tobacco campaign launched to prevent lung cancer

The Australian Federal Government is backing a $61 million advertising campaign to stop smoking. This is the nation’s biggest anti-tobacco campaign. The message is graphic and simple: every cigarette brings cancer closer. Health groups have backed the campaign but advertising industry experts say the public has become increasingly immune to scare campaigns.

31 Jan 2011